FPR1 and neoplasm: In addition, the pharmacological modulation of FPR1 activity through ALOX5/15 expression and production of pro-resolving mediators resolvin D1 and lipoxin B4, which transduce anti-inflammatory signals, reduced the rate of GC progression by inhibiting inflammatory and angiogenic processes in the tumor microenvironment [18].